Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice by Leroy, B, Ballinger, M, Baran-Marszak, F, Bond, G, Braithwaite, A, Concin, N, Donehower, L, El-Deiry, W, Fenaux, P, Gaidano, G, Langerød, A, Hellstrom-Lindberg, E, Iggo, R, Lehmann-Che, J, Mai, P, Malkin, D, Moll, U, Myers, J, Nichols, K, Pospisilova, S, Ashton-Prolla, P, Rossi, D, Savage, S, Strong, L, Tonin, P, Zeillinger, R, Zenz, T, Fraumeni, J, Taschner, P, Hainaut, P, Soussi, T

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers by Fagnan, A, Bagger, FO, Piqué-Borràs, M-R, Ignacimouttou, C, Caulier, A, Lopez, C, Robert, E, Uzan, B, Gelsi-Boyer, V, Aid, Z, Thirant, C, Moll, U, Tauchmann, S, Kurtovic-Kozaric, A, Maciejewski, JP, Dierks, C, Spinelli, O, Salmoiraghi, S, Pabst, T, Shimoda, K, Deleuze, V, Lapillonne, H, Sweeney, C, Mansat-De Mas, V, Leite, B, Kadri, Z, Malinge, S, de Botton, S, Micol, J-B, Kile, BT, Carmichael, CL, Iacobucci, I, Mullighan, CG, Carroll, MP, Valent, P, Bernard, OA, Delabesse, E, Vyas, P, Birnbaum, D, Anguita, E, Garcon, L, Soler, E, Schwaller, J, Mercher, T